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Abstract
MicroRNAs (miRNAs) are a class of small, noncoding RNAs critically involved in a wide spectrum of normal and 
pathological processes of cells or tissues by fine-tuning the signals important for stem cell development, cell 
differentiation, cell cycle regulation, apoptosis, and transformation. Considerable progress has been made in the past 
few years in understanding the transcription, biogenesis and functional regulation of miRNAs. Numerous studies have 
implicated altered expression of miRNAs in human cancers, suggesting that aberrant expression of miRNAs is one of 
the hallmarks for carcinogenesis. In this review, we briefly discuss most recent discoveries on the regulation of miRNAs 
at the level of microprocessor-mediated biogenesis of miRNAs.
Introduction
MicroRNAs (miRNAs) are endogenously synthesized
small non-coding RNAs that regulate gene expression by
interfering with protein translational machinery and/or
inducing degradation of target mRNAs [1]. Since the dis-
covery of miRNAs, much effort has been made to under-
stand the mechanisms by which miRNAs are synthesized
and involved in cell lineage development and human dis-
eases, especially, cancer. It is imperative that scientists
continue to delineate how the biogenesis of these miR-
NAs is controlled by the cellular processing machinery, so
that one may better understand how to modulate their
expression or function as it contributes to a unique dis-
ease state. Recent research shows the involvement of
additional proteins that modulate the function of the
miRNA processing machinery, the Drosha processing
complex, or microprocessor. This article reviews these
new findings and discusses the potential for targeting
these regulatory pathways in cancer therapy.
1. MicroRNA biogenesis
It has been well-established that the biogenesis of
microRNAs (miRNAs) involves three step-wise pro-
cesses, including transcription of primary miRNAs (pri-
miRNAs) from the miRNA genes [2], partially processed
precursor miRNAs (pre-miRNAs) in nuclei [3] and the
mature miRNAs that were generated in the cytoplasm
(Fig. 1). Pri-miRNA is typically a large RNA polymerase
pol II-derived transcript whose tertiary structure forms
stem loop structures. The stem loop is cleaved off by the
microprocessor machinery, Drosha complex, to form
~60-100 nucleotide long pre-miRNA, which is further
processed into ~22 nucleotide long mature miRNAs by
Dicer, a RNase III enzyme, following translocation from
the nuclei to cytoplasm [4].
After successful cleavage, the pre-miRNA is bound by
exportin-5 in a ran-GTP dependant manner and
exported from the nucleus [5-7]. Binding of pre-miRNA
by exportin-5 is dependent upon the stem of the miRNA,
requiring a length of 16-18 base pairs, and alterations in
the 3' overhang will affect the efficiency of exportin-5
binding[8]. Interestingly, reduced binding of exportin-5
by reduction of the protein itself or alteration in the
miRNA structure causes a reduced expression of the
mature miRNA, without buildup of pre-miRNA in the
nucleus [5]. This suggests that exportin-5 may play a pro-
tective role during miRNA transport to the cytoplasm [8].
Once in the cytoplasm, the pre-miRNA is released from
exportin-5 after the hydrolysis of GTP , and is free to be
processed further.
In the cytoplasm, pre-miRNA undergoes the next step
of processing mediated by Dicer to produce the mature
miRNA. The RNase III enzyme, Dicer, was found to
cleave RNAs into ~22 nucleotide products [9-11]. This
cleavage occurs in an ATP independent manner, through
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which the loop structure and 3' overhang are removed
[12]. Recognition and correct cleavage of the pre-miRNA
are determined by the different domains of Dicer. Dicer
contains a PAZ domain which recognizes the 3' end of the
pre-miRNA, and the rest of the molecule acts as a molec-
ular ruler directing the RNase III domains to cleave the 3'
overhang and the loop structure to generate the mature
miRNA [13]. After cleavage, one strand of the miRNA
duplex is preferentially incorporated into the RISC com-
plex. The selection of one strand over the other is based
upon thermodynamic properties of the duplex, and the
strand with the less thermodynamical stability at the 5'
end is usually selected [14]. The mature miRNA bound to
RISC then associates with an Argonaute protein, most
commonly Ago2, and directs binding of the RISC com-
plex to partially complementary sites in the 3'-UTRs of
targeting mRNAs [15].
Previous observations suggested that the specificity of
miRNA is determined by the sequence complementarity
between bases 2-8 on the 5' end of the miRNA, termed
the seed sequence, and the target mRNAs [16,17]. A
recent study appears to oppose this seed sequence pairing
mechanism, and identifies binding and repression of
mRNA by several "seedless" miRNA-mRNA duplexes
[18]. In a microarray study for proteins down regulated by
miR-24 expression, it was observed that multiple genes
whose expression was reduced do not have predictable
t a r g e t  s e q u e n c e s .  U s i n g  a n  a l g o r i t h m  t h a t  d o e s  n o t
require a seed match, it was further confirmed that the
miR-24 targeting sequences are indeed within the 3'
UTRs of the repressed genes [18].
Figure 1 MicroRNA (miRNA) production and processing. The pri-miRNA transcript is transcribed by RNA polymerase II. The stem loop structure is 
cleaved off by the microprocessor to generate pre-miRNA. The pre-miRNA is exported to the cytoplasm by exportin5 in a ran-GTP dependent manner. 
Once in the cytoplasm, the pre-miRNA is processed by Dicer creating a single stranded mature miRNA. This mature miRNA is bound by the RISC com-
plex, guiding it to the 3'UTR of target mRNAs, leading to repression of protein expression.

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There are multiple mechanisms by which miRNAs
downregulate gene expression, some of which are still in
controversy. These mechanisms have been reviewed in-
depth elsewhere [19]. Briefly, mRNAs have been
observed to be repressed by three major processes
including endonucleolytic cleavage, mRNA degradation
by deadenylation, and inhibition of translation initiation.
Similar to siRNA-mediated mRNA degradation, the
endonucleolytic cleavage of mRNA by miRNA requires
perfect or near perfect complementarity between miRNA
and the target mRNA. If such a condition is satisfied, pro-
teins within the RISC complex are then able to cleave the
mRNA, leading to its degradation and silencing [20]. This
gene silencing process has been shown to occur in multi-
ple organisms including mammals. Of note however, this
mechanism of gene regulation rarely occurs in mamma-
lian cells because nearly all miRNA-mRNA interactions
have significant mismatches [17,21-23].
Inhibition of translation initiation is another widely
studied mechanism of miRNA-induced gene silencing. In
2005 Pillai et al. found that a miRNA-targeted reporter
mRNA sedimented with small polysomes in HeLa cells,
which indicates the repression occurred at translation
initiation. In the same publication, they also showed that
reporter constructs which are not dependant on the 7-
methyl guanosine cap structure did not undergo repres-
sion, and suggested that miRNPs are capable of binding
to the cap structure [24]. A motif was later found within
AGO2 that was indeed capable of binding to the 5' cap
structure of mRNA, which could then compete with
eIF4E that is necessary for initiation of translation [25].
Cellular localization is another mechanism by which
miRNA might mediate repression of mRNA translation.
T h e r e  i s  ev i d e n c e  s u g g e s t i n g  t h a t  s o m e  m i R N P - bo u n d
mRNAs localize to p-bodies within the cytoplasm. The p-
bodies are cytoplasmic foci that contain mRNAs that are
not actively undergoing translation. The p-bodies also
contain proteins that are responsible for mRNA degrada-
tion [26]. Several observations suggest that mRNAs
within the p-bodies are being repressed by miRNA that
are co-localized in these foci. However, a detailed mecha-
nism by which the repression occurs has yet to be fully
determined. In addition, the deadenylation of mature
mRNA has been implicated as a mechanism by which
miRNAs are able to repress protein translation within the
p-bodies. It was believed that GW182, a protein impor-
tant for deadenylation of mRNAs, localizes in p-bodies
and is able to interact with AGO1. This interaction leads
to recruitment of decapping complexes and subsequent
degradation of the miRNP-bound mRNA [27-29].
2. Microprocessor and pri-miRNA processing
The pri-miRNAs transcribed from miRNA genes usually
exhibit a size of several thousands of nucleotides long,
whereas the size of mature miRNAs is only about 22 base
pairs [30]. As briefly mentioned earlier, the generation of
mature miRNA, encoded by either an intron of protein-
coding gene or intergenic non-coding transcription unit,
requires two sequential endonucleolytic cleavages by
RNase III enzymes. A nuclear protein, Drosha, is the first
enzyme to catalyze such processing. It is believed that
Drosha is able to cleave intronic pri-miRNA without
interference with the splicing of the precursor mRNA
(pre-mRNA) [31]. There is also evidence indicating that
cleavage of pri-miRNA by Drosha can be closely coupled
with transcription of the pri-miRNAs from either
intronic or intergenic miRNA genes [31].
Accumulating evidence suggests that processing of pri-
miRNA by Drosha itself is insufficient and often errone-
ous, since imprecise cleavage occurred by the recombi-
nant Drosha protein [32]. Inaccuracy of pri-miRNA
cleavage will result in production of pre-miRNAs with
altered hairpin secondary structure and identities. To
ensure efficient and precise processing of pri-miRNA by
Drosha, a number of co-factors are necessarily needed.
Indeed, protein fractionation by affinity chromatography
revealed that Drosha is present in protein complexes with
different sizes in vivo [32,33]. The study performed by
Gregory et al. showed association of Drosha with 2 differ-
ent complexes, a large complex with ~20 proteins and a
small complex consisting of Drosha and DiGeorge syn-
drome critical region 8 (DGCR8) [32]. The association of
Drosha with these proteins forms microprocessors to
ensure the fidelity and activity of Drosha cleavage on pri-
miRNA [32]. DGCR8 is a protein found within the
DiGeorge syndrome critical region and was revealed to
be essential for the processing of pri-miRNA to pre-
miRNA by Drosha. At about the same time, Han et al.
also identified DGCR8 as a critical player in miRNA pro-
cessing and demonstrated that the microprocessor com-
plex may be composed of multiple DGCR8 and Drosha
molecules, possibly creating a dynamic processing struc-
ture [33]. Because most pri-miRNAs have similar struc-
tures typified by a terminal loop, a double stranded stem,
and single stranded flanking sequences, it was speculated
that this common structure may be the determining fac-
tor that regulates pri-miRNA cleavage (Fig. 2). There is
evidence indicating that both the terminal loop and single
stranded flanking sequences are important for processing
efficiency [4,34,35]. An in-depth look at the molecular
mechanisms controlling the binding of pri-miRNAs by
the microprocessor complex suggests that DGCR8 is
responsible for the binding of the complex to the pri-
miRNA stem-loop. DGCR8 recognizes both the single
stranded flanks and the double stranded stem, and then
acts as a ruler guiding Drosha to cleave the molecule in
the correct place, 11 base pairs up the stem from the
ssRNA-dsRNA junction (Fig. 2) [36].Beezhold et al. Molecular Cancer 2010, 9:134
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In addition to DGCR8, other well-characterized pro-
teins in the microprocessor which facilitate the activity of
Drosha include two DEAD-box RNA helicases p68 and
p72 [32,37]. Both p68 and p72 are originally identified as
ATP-dependent RNA helicases important for pre-mRNA
and pre-rRNA splicing by association with spliceosome
complexes [38]. Genetic disruption of either p68 or p72
in mice is lethal.
Surveying miRNA expression profiling using embryo
fibroblast cells (MEF) suggests about 35% reduction of
pre-miRNA and mature miRNA expression in p68 or p72
gene knockout MEFs relative to the wild type MEFs.
Intriguingly, the level of pri-miRNAs is comparable
between the knockout MEFs and the wild-type MEFs,
indicating contribution of p68 or p72 to the Drosha-
mediated pri-miRNA processing [39]. Direct evidence of
p68 and p72 in pri-miRNA processing was provided by
demonstrating their interaction with the Drosha and
DGCR8 proteins in an immunoprecipitation-mass spec-
tromic analysis [32,37].
3. Regulation of the microprocessor by SMADS
The first evidence showing additional proteins binding to
and modulating the function of the Drosha complex was
provided by Davis et al. in 2008 [40]. Through studying
which miRNAs might play a role in the phenotypic
changes of the vascular smooth muscle cells in response
to TGF-β signaling, they found that miR-21 and miR-
199a were induced by BMP4 and TGF-β stimulation. Fur-
ther studies indicate that such an induction occurred at
the post-transcriptional level because BMP4 or TGF-β
rapidly induces pre-miR-21 and mature miR-21 but not
Figure 2 Modulation of microprocessor function by SMAD, p53 and Ars2 in response to TGF-β, p53 and stress signaling, respectively.
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pri-miR-21. Indeed, the expression of pri-miR-21 stayed
stable following the activation of the TGF-β signaling.
The induction of pre-miR-21 and miR-21 by BMP4 or
TGF-β was blocked in the cells when expression of
SMAD proteins was repressed by siRNA knock-down.
Previous studies suggest that the MH2 domain on the
carboxyl-terminus of SMAD proteins is capable of bind-
ing to p68, the RNA helicase associated with the Drosha
complex [41]. This conclusion was supported by Davis et
al. [40] who demonstrated direct interaction of p68 with
SMAD1, 3, and 5 in a GST-pull down experiment. The
interaction of Drosha with the p68/SMAD complex
occurred only under conditions where the miRNA tran-
scripts were intact. Furthermore, RNA co-immunopre-
cipitation confirmed the specific regulation of SMADs on
the microprocessors of miR-21 and miR-199a, but not
miR-214, in response to BMP4 or TGF-β (Fig. 2).
Activation of SMAD proteins by TGF-β has long been
assumed as a mechanism for inducing epithelial to mes-
enchymal transition (EMT) and overall cancer cell
growth. Adding to this role, the above study demon-
strates an additional function of TGF-β being able to
increase the expression of miRNAs 21 and 199a. MiR-21
is the most commonly over-expressed miRNA in cancers
[42]. Over-expression of miR-21 has been reported in
more than 15 different malignancies [43]. The oncogenic
potential of miR-21 is largely attributed to its involve-
ment in several intracellular signaling pathways, includ-
ing the activation of AKT [44] and antagonizing the
expression of the pro-apoptotic protein PDCD4 [45].
Expression of miR-199a has also been associated with
cancers. One study suggests that leukemias with higher
expression of miR-199a exhibit a worse prognosis [46].
Several other studies, however, show that a loss in expres-
sion of miR-199a, enhanced tumor progression by an
enhancement of IKKβ expression and its induced inflam-
matory and tumorigenic signals in ovarian cancer [47].
TGF-β and SMAD4 have also been recognized as key
players in inducing transcription of miR-155 and miR-
214, two other oncogenic miRNAs [48]. Elevated miR-
155 represses RhoA protein expression, reduces the abil-
ity of epithelial cells to form tight junctions, and enhances
a tumors' ability of metastasis [48]. In ovarian cancer,
miR-214 is overexpressed, leading to a sustained activa-
tion of the Akt kinases by down-regulation of PTEN, a
negative regulator of Akt signaling. Decrease in PTEN
expression, thus, causes an aberrant activation of Akt and
resistance of the tumor cells to chemotherapy, such as
cisplatin treatment [49].
The above reports detailing regulation of Drosha pro-
cessing by SMADs in response to TGF-β signaling are of
particular interest. This modulation appears to be spe-
cific to a subset of miRNAs, and it will be important to
determine what other miRNAs are regulated by this same
mechanism and what molecular events govern such regu-
lation. It appears that the binding of SMAD proteins to
the Drosha microprocessor stabilizes the formation of the
complex on a specific set of pri-miRNAs. Accordingly, it
will be important to determine the downstream targets of
these miRNAs and whether regulation of miRNA pro-
cessing is a major mechanism of TGF-β in cell transfor-
mation and carcinogenesis.
4. p53 and miRNA processing
The tumor suppressor p53 is perhaps the most inten-
sively studied protein in cell biology and cancer. As a
transcription factor, the tumor suppressor function of
p53 is achieved largely by transcriptional up-regulation of
a number of pro-apoptotic proteins. A recent study by
Suzuki and colleagues demonstrates a novel mechanism
of p53 in tumor suppression by regulating miRNA bio-
genesis at the level of Drosha microprocessor [50]. The
interaction of p53 with p68, a protein associated with the
Drosha microprocessor, has been previously demon-
strated [51]. In the latest study, it was noted that p53 is
capable of interacting with p68 and p72, both of which
are Drosha-associated RNA helicases (Fig. 2). Using dox-
orubicin as a DNA damaging agent and p53 inducer in
human colon cancer cell line HCT116, the expression of a
subset of miRNAs was up-regulated. These miRNAs
include miR-15a, miR-16-1, miR-23a, miR-26a, miR-103,
miR-143, miR-145, miR-203, as well as miR-34a that had
previously been determined to be induced by p53 [52].
Upon examination of the expression levels of pri-, pre-
and mature miRNAs for each of the miRNAs regulated by
doxorubicin, as expected, all species of miR-34a, a tran-
scriptional target of p53, were upregulated. Interestingly,
several other miRNAs showed increases of pre- and
mature miRNA species, but not the pri-miRNA tran-
scripts, suggesting that the regulation of p53 for some of
these miRNAs is independent of transcription. Further-
more, cancer-associated p53 mutants fail to bind p68 or
induce miRNA processing. Overexpression of each of
these p53-regulated miRNAs substantially decreased the
rate of cell proliferation. Taken together, these data
clearly indicate that mutation of p53 in cancers hinders
the maturation of several miRNAs important for tumor
suppression and leads to an increased tumorigenic poten-
tial.
The involvement of p53 in miRNA biogenesis post-
transcriptionally provides evidence of a global control
mechanism for subsets of miRNAs involved in similar
cellular functions. The p53 transcriptional target, miR-
34a, was shown to repress tumor progression in multiple
cancers [53-55] and has recently been found to target c-
met and Notch1/Notch2 in glioblastomas [56]. Interest-
ingly, expression of miR-15a and miR-16-1 is often
reduced in tumors. Both miR-15a and miR-16-1 haveBeezhold et al. Molecular Cancer 2010, 9:134
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been shown to target the anti-apoptotic protein, BCL2
[57,58]. This cluster of miRNAs is also observed to be
able to target additional proteins such as Cyclin D1 and
WNT3A, which promote tumorigenesis [59]. Decreased
expression of miR-143 and miR-145 has been strongly
linked to colon cancer [60-62]. MiR-143 has been shown
to target KRAS [63] and DNA methyltransferase 3A [62].
In breast cancer, loss of miR-145 resulted in an elevation
of rhotekin (RTKN), a scaffolding protein for Rho-GTP
that is involved in cell proliferation [64].
The involvement of p53 in miRNA biogenesis was
unexpected. The capability of p53 to regulate miRNA
expression obviously strengthens its tumor suppressor
function further. The questions that remain unanswered
are why association of p53 with the Drosha microproces-
sor only regulates a selected subset of miRNAs but not
others and how does p53 alter the recognition and pro-
cessing dynamics of the Drosha complex toward the pri-
miRNA repertoire. Nevertheless, the discovery of p53
regulation on miRNA processing confirms that p53 is a
powerful suppressor for cancer formation. Loss of p53 as
observed in multiple cancers, therefore, will not only
weaken the checkpoint mechanisms of the cells but also
impair the generation of those tumor suppressor-like
miRNAs.
5. ARS2 regulation of miRNA processing
Arsenic Resistance protein 2 (Ars2) is a protein whose
expression is strongly linked to the proliferation of cells
especially during embryonic development [65]. Recently
two studies have been published linking Ars2 expression
to miRNA processing. The study by Gruber et al. [66]
show that in addition to its role in cell proliferation,
depletion of Ars2 in mammalian cells repressed miRNA-
mediated silencing of reporter genes. After siRNA knock-
down of Ars2, the ability of let-7 to repress the expression
of a luciferase reporter construct was significantly
reduced. Addition of the let-7 duplex RNA was able to
reverse the loss of reporter repression, indicating that
Ars2 does not function down-stream of Drosha process-
ing. Immunoprecipitation of Drosha proteins was able to
pull down Ars2, while the same experiment with Dicer
did not. This further indicates that repression of miRNA
function occurs at the Drosha processing step (F ig. 2).
Previous research performed on SERRATE, a plant
homolog of Ars2, indicates that Ars2 was responsible for
regulating the appropriate processing of miRNA by
Drosha [67]. However, Gruber et al. found that Ars2 was
not required for processing of all miRNAs, but only for a
subset containing let-7 and miR-21. After screening for
factors important in antiviral defense in Drosophila,
Sabin et al. simultaneously observed a similar activity of
Ars2 in miRNA processing in Drosophila with viral infec-
tion [68]. They identified that Ars2 is critical for intrinsic
antiviral defense in Drosophila. Loss of Ars2 leads to a
pronounced increase in viral replication of several RNA
viruses in both cell culture and adult flies. Using an over-
expression strategy, Sabin et al. [68] also demonstrate that
Ars2 was capable of binding to Pasha, also known as
DGCR8 in mammals, the double-stranded RNA binding
partner of Drosha. Additional experiments implied inter-
action between Ars2 and the nuclear cap-binding com-
plex (CBC) that recognizes and binds to the 5'-cap of pri-
miRNA transcripts. Based on all of these observations,
two nonexclusive models for the role of Ars2 in miRNA
processing were proposed. The first is the so-called
bridging model, in which both Ars2 and CBC bind pri-
miRNA transcripts followed by recruitment of the
Drosha microprocessor by Ars2. In the second model,
Ars2 acts as a cofactor for Drosha's enzymatic activity by
enhancing the overall processing activity and fidelity of
the microprocessor [68].
The discovery of Ars2 in miRNA processing further
emphasizes the point that miRNA biogenesis and activity
are highly regulated processes involving multiple proteins
at various stages. Although Ars2 is a protein which has
not been extensively studied, early reports indicating its
contributions to cell proliferation and more recent stud-
ies showing its role in miRNA processing suggest that
Ars2 may be a potential target for therapeutic interven-
tion in various disease states including cancer.
6. Cell-to-cell contact affects miRNA processing
The regulation of microRNA processing has been found
to be affected by the confluence of the culture or the
intensity of cell-to-cell contacts. Hwang et al. found that
as cultures reach confluence, the expression of most of
the miRNAs that they studied also increased [69]. They
were able to show that this effect occurred across multi-
ple cell lines and was typified by an accumulation of pre-
and mature miRNA. This change in miRNA levels
appears to be independent of the status of cell prolifera-
tion, conditions of the cell culture media, or the density of
the cells in culture. This indicates that an increase in cell-
to-cell contacts was the impetus for the increase in
miRNA processing. The authors further determined that
the abundance of pri-miRNA transcript was not
increased by the status of cell confluence with the inter-
esting exception of miR-34a. Such information along with
additional experiments indicated that this regulation was
caused by an increase in efficiency of the Drosha micro-
processor as well as formation of mature miRISC com-
plexes at the Dicer processing step [69].
In light of the study discussed earlier indicating the role
of p53 in Drosha processing, it is very likely that this reg-
ulation could be due to p53 activity. Along with the non-
transcriptional induction of miR-15a, miR-16, miR-26a,
and miR-145, the observation that miR-34a was the onlyBeezhold et al. Molecular Cancer 2010, 9:134
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transcriptionally regulated miRNA in both studies is the
key to linking these two studies together. Furthermore,
p53 has been implicated as an important mediator for the
density-dependant growth inhibition of cells. One study
shows that inhibition of p53 led to the loss of density-
dependent growth inhibition, leading to increased cell
density and decreased apoptosis. While no increase of
p53 expression was observed, basal levels were sufficient
to cause growth arrest [70]. The studies by Suzuki et al.
and Hwang et al. may, at least in part, be able to explain
how p53 can cause density-dependent growth inhibition.
While most of the miRNAs observed to be up regulated
by Hwang et al. are involved in growth inhibition, some
are strongly associated with proliferation and tumorigen-
esis, like miR-21. This may indicate that additional pro-
teins are involved in the effect of cell confluence- or cell-
to-cell interaction-mediated miRNA processing. It would
be of interest to determine if the effect seen on processing
efficiency by Dicer and miRISC formation is also due to
p53 activity or to additional modulators of miRNA pro-
cessing.
7. Inhibition of miRNA biogenesis by estrogen
Estrogen hormones are well known regulators for tran-
scription and post-transcriptional events of a number of
genes through binding to their specific nuclear estrogen
receptors (ERs), ERα or ERβ. Although both receptors
exhibit a similar affinity toward estrogen, a distinction in
tissue distribution between ERα and ERβ has long been
recognized. ERα is mainly found in endometrium, breast
cancer cells, ovarian stroma cells, and in the hypothala-
mus, whereas ERβ appears to be ubiquitously expressed.
By using embryos derived from female mice with a
genetic deficiency of ERα, a recent study by Yamagata et
al. [71] reported an upregulation of some miRNAs. Con-
versely, such an upregulation was reversed by estrogen
(E2) treatment, suggesting that estrogen and its receptor
signaling are negative regulators for certain miRNAs,
including miR-16, miR-26a, miR-29a, miR-125a, miR-
143, miR-145, miR-195, etc.. Further studies indicate that
the negative regulation of ERα on these miRNAs
occurred at the level of pri-miRNA processing, rather
than transcription. A direct physical association of the
E2-bound ERα with Drosha microprocessor components,
p68 and p72, was noted in an immunoprecipitation assay.
The regulation of ERα on miRNA biogenesis was also val-
idated in human cells. Collectively, these data suggest that
E2-ERa signaling is antagonistic for miRNA processing,
possibly through direct interaction between ERα and
p68/p72, leading to dissociation of the Drosha micropro-
cessor from a subset of pri-miRNAs.
The evidence showing inhibitory roles of ERα on the
biogenesis of a select subset of miRNAs provides a new
explanation for the molecular mechanisms of the ERα
positive breast cancers. Due to its negative regulation on
some of these tumor suppressor-like miRNAs, including
miR-16 and miR-26a, ERα can amplify the tumorigenic
signals from VEGF [71], EZH2 [72] and some oncogenes
that are targeted by miR-16 or miR-26a in breast epithe-
lial cells. Thus, there is strong indication for pursuing an
ERα-based therapeutic approach. First, suppression of
the ERα signaling by selective ERα modulators, such as
tamoxifen, can inactivate transcriptional regulation of
ERα on some growth factors important for the transfor-
mation of the cells. Second, blocking ERα signaling will
enhance the tumor suppressive potential of the cells by
promoting the biogenesis of those tumor suppressor-like
miRNAs, which limit the growth and vascularization of
the tumors.
Summary and Conclusions
An underlying theme in the regulation of miRNA biogen-
esis at the Drosha processing step seems to be that regu-
latory proteins selectively alter the expression of certain
subsets of miRNAs. This is not entirely surprising, as the
cellular functions of miRNAs are diverse, and global up-
regulation or down-regulation of all miRNAs might cause
havoc on cellular systems. The miRNA subsets whose
expression are altered by the regulatory proteins dis-
cussed above seem to be in line with the traditionally
accepted roles for those proteins. As more and more reg-
ulatory proteins are discovered for all steps of miRNA
production and processing, it is most likely that this
theme will be extended. The activation of Smad proteins
is associated with cell growth and transformation, and
the miRNAs that are regulated by Smads are associated
with similar effects. On the other hand, expression and
activation of p53 is a well known mechanism of cell cycle
arrest and apoptosis, and its downstream miRNAs can be
effectors of the same pathways. While Ars2 is not a very
well-studied protein and its detailed function remains to
be fully elucidated, recent research shows that it is
involved in cell proliferation. Likewise, the miRNAs that
Ars2 has been shown to regulate are involved in similar
cellular functions. Additional research should be done to
delineate exactly which miRNAs are in each regulated
subset. This information would be useful for determining
if therapeutic intervention of proteins, such as Ars2,
would be a fruitful endeavor.
One exception to the theme is the observed activation
of miRNA biogenesis by cell-to-cell contacts. This effect
appears to be global (with few exceptions), including the
expression of miRNA that have historically opposite
effects. Cellular signaling that occurs during quiescence
is highly complex, and the study by Hwang et al. now
places miRNA expression into the mix [69].
As the study of miRNA biogenesis continues, it is
apparent that more proteins will be discovered to pla yBeezhold et al. Molecular Cancer 2010, 9:134
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regulatory roles at various processing steps. It will be
important to determine whether or not these proteins or
processing pathways are legitimate targets for therapeutic
intervention. It is becoming increasingly clear that sub-
sets of miRNA play important roles in multiple disease
states. If there are master regulators of expression of
these subsets, they could be potential targets for inter-
vention and may be critical for the alleviation of symp-
toms or reversal of disease.
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